Home > EURETINA Highlights
    • FILTER YOUR SEARCH
    Speciality:
    More Specialities

    • EURETINA Highlights

    Macular Degeneration
    Kyoko Ohno-Matsui, EURETINA 2021: Advantages and Limitations of a Deep Learning Algorithm

    We were delighted to speak with Kyoko Ohno-Matsui (Tokyo Medical and Dental University, Tokyo, Japan) about the potential advantages and limitations of a deep learning algorithm for automated detection of myopic maculopathy and pathologic myopia in fundus images, and the challenges in developing this algorithm. Questions What are the potential advantages and limitations of a […]

    Macular Degeneration
    Kyoko Ohno-Matsui, EURETINA 2021: Results of a Study Evaluating a Deep Learning Algorithm

    It was a pleasure to catch up with Kyoko Ohno-Matsui (Tokyo Medical and Dental University, Tokyo, Japan), who discussed the results of her study evaluating a deep learning algorithm for automated detection of myopic maculopathy and pathologic myopia in fundus images. Questions What were the methodology and outcome measures of your study evaluating a deep […]

    Retina/Vitreous
    Roxane Hillier, EURETINA 2021: Retinal Recovery after Pneumatic Retinopexy

    We were delighted to catch up with Roxane Hillier (Newcastle Eye Centre, Newcastle, UK), who gave us her insights on the impact of pneumatic retinopexy (PnR) on vision-related quality of life, and retinal recovery following PnR. Questions What is the impact of pneumatic retinopexy (PnR) on vision-related quality of life? (00:13) What is known about […]

    Retina/Vitreous
    Roxane Hillier, EURETINA 2021: Pneumatic Retinopexy for the Management of Rhegmatogenous Retinal Detachment

    It was wonderful to speak with Roxane Hillier (Newcastle Eye Centre, Newcastle, UK) about the advantages of pneumatic retinopexy compared with pars plana vitrectomy for the management of rhegmatogenous retinal detachment. Questions Why has the optimal surgical technique for the treatment of rhegmatogenous retinal detachment (RRD) been controversial? (00:12) What are the advantages of pneumatic […]

    Retina/Vitreous
    Paisan Ruamviboonsuk, EURETINA 2021: Artificial Intelligence Platforms for Diagnosis and Screening for Polypoidal Choroidal Vasculopathy

    We enjoyed catching up with Paisan Ruamviboonsuk (Rajavithi Hospital, Bangkok, Thailand) about the clinical evidence supporting the use of artificial intelligence platforms in diagnosis and screening for polypoidal choroidal vasculopathy, and the unanswered questions that remain. Questions What clinical evidence supports the use of artificial intelligence platforms in the diagnosis and screening for polypoidal choroidal […]

    Retina/Vitreous
    Paisan Ruamviboonsuk, EURETINA 2021: Artificial Intelligence in Ophthalmology

    It was a pleasure to speak with Paisan Ruamviboonsuk (Rajavithi Hospital, Bangkok, Thailand) about his views on artificial intelligence in ophthalmology, specifically for diagnosis and screening for polypoidal choroidal vasculopathy. Questions Could you give us a brief overview of your research in artificial intelligence (AI) in ophthalmology? (00:18) What is the potential of AI in […]

    Retina/Vitreous
    Gemmy Cheung, EURETINA 2021: New Insight on Polypoidal Choroidal Vasculopathy

    We were delighted to speak with Gemmy Cheung (Singapore National Eye Center, Singapore) about recent research in the pathogenesis of polypoidal choroidal vasculopathy, and the gaps in knowledge that remain. Questions Could you give us a brief overview of the epidemiology and clinical features of polypoidal choroidal vasculopathy (PCV)? (00:10) What has recent research taught […]

    Paediatric Ophthalmology
    Birgit Lorenz, EURETINA 2021: Detection of Macular Problems in Retinopathy of Prematurity

    We were delighted to catch up with Birgit Lorenz (Justus-Lieibig-University Giessen, Hesse, Germany), who discussed detection of macular problems in retinopathy of prematurity, unanswered questions and future studies. Questions What have we learned about the detection of macular problems in retinopathy of prematurity? (00:32) What questions remain unanswered and what future studies are planned? (02:08) […]

    Paediatric Ophthalmology
    Birgit Lorenz, EURETINA 2021: Retinopathy of Prematurity – Clinical Features and treatment

    It was a pleasure to speak with Birgit Lorenz (Justus-Lieibig-University Giessen, Hesse, Germany) about retinopathy of prematurity, its clinical features and treatment, and what imaging studies have taught us about the development of macular development arrest. Questions Could you tell us a little about retinopathy of prematurity, its clinical features and treatment? (00:31) What have […]

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72